Skip Nav Destination
A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Issue Archive
August 9 2012
In this Issue
Table of Contents
Inside Blood
Blood Work
Plenary Paper
Perspectives
Review Article
How I Treat
Clinical Trials and Observations
A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
Clinical Trials & Observations
Francesco Passamonti,Jürgen Thiele,Francois Girodon,Elisa Rumi,Alessandra Carobbio,Heinz Gisslinger,Hans Michael Kvasnicka,Marco Ruggeri,Maria Luigia Randi,Naseema Gangat,Alessandro Maria Vannucchi,Andrea Gianatti,Bettina Gisslinger,Leonhard Müllauer,Francesco Rodeghiero,Emanuele S. G. d'Amore,Irene Bertozzi,Curtis A. Hanson,Emanuela Boveri,Filippo Marino,Margherita Maffioli,Domenica Caramazza,Elisabetta Antonioli,Valentina Carrai,Veronika Buxhofer-Ausch,Cristiana Pascutto,Mario Cazzola,Tiziano Barbui,Ayalew Tefferi
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Clinical Trials & Observations
Srdan Verstovsek,Hagop M. Kantarjian,Zeev Estrov,Jorge E. Cortes,Deborah A. Thomas,Tapan Kadia,Sherry Pierce,Elias Jabbour,Gautham Borthakur,Elisa Rumi,Ester Pungolino,Enrica Morra,Domenica Caramazza,Mario Cazzola,Francesco Passamonti
Hematopoiesis and Stem Cells
Immunobiology
The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development
Masaya Baba,Jonathan R. Keller,Hong-Wei Sun,Wolfgang Resch,Stefan Kuchen,Hyung Chan Suh,Hisashi Hasumi,Yukiko Hasumi,Kyong-Rim Kieffer-Kwon,Carme Gallego Gonzalez,Robert M. Hughes,Mara E. Klein,Hyoungbin F. Oh,Paul Bible,Eileen Southon,Lino Tessarollo,Laura S. Schmidt,W. Marston Linehan,Rafael Casellas
Lymphoid Neoplasia
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Alison T. Stopeck,Joseph M. Unger,Lisa M. Rimsza,Michael LeBlanc,Brent Farnsworth,Maria Iannone,Martha J. Glenn,Richard I. Fisher,Thomas P. Miller
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
Emilia Mahoney,David M. Lucas,Sneha V. Gupta,Amy J. Wagner,Sarah E. M. Herman,Lisa L. Smith,Yuh-Ying Yeh,Leslie Andritsos,Jeffrey A. Jones,Joseph M. Flynn,Kristie A. Blum,Xiaoli Zhang,Amy Lehman,Hui Kong,Metin Gurcan,Michael R. Grever,Amy J. Johnson,John C. Byrd
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma
Luca Agnelli,on behalf of the European T-Cell Lymphoma Study Group,Elisabetta Mereu,on behalf of the European T-Cell Lymphoma Study Group,Elisa Pellegrino,on behalf of the European T-Cell Lymphoma Study Group,Tania Limongi,on behalf of the European T-Cell Lymphoma Study Group,Ivo Kwee,on behalf of the European T-Cell Lymphoma Study Group,Elisa Bergaggio,on behalf of the European T-Cell Lymphoma Study Group,Maurilio Ponzoni,on behalf of the European T-Cell Lymphoma Study Group,Alberto Zamò,on behalf of the European T-Cell Lymphoma Study Group,Javeed Iqbal,on behalf of the European T-Cell Lymphoma Study Group,Pier Paolo Piccaluga,on behalf of the European T-Cell Lymphoma Study Group,Antonino Neri,on behalf of the European T-Cell Lymphoma Study Group,Wing C. Chan,on behalf of the European T-Cell Lymphoma Study Group,Stefano Pileri,on behalf of the European T-Cell Lymphoma Study Group,Francesco Bertoni,on behalf of the European T-Cell Lymphoma Study Group,Giorgio Inghirami,on behalf of the European T-Cell Lymphoma Study Group,Roberto Piva,on behalf of the European T-Cell Lymphoma Study Group
Myeloid Neoplasia
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
Laura Barreyro,Britta Will,Boris Bartholdy,Li Zhou,Tihomira I. Todorova,Robert F. Stanley,Susana Ben-Neriah,Cristina Montagna,Samir Parekh,Andrea Pellagatti,Jacqueline Boultwood,Elisabeth Paietta,Rhett P. Ketterling,Larry Cripe,Hugo F. Fernandez,Peter L. Greenberg,Martin S. Tallman,Christian Steidl,Constantine S. Mitsiades,Amit Verma,Ulrich Steidl
Phagocytes, Granulocytes, and Myelopoiesis
Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery
Takayuki Tanaka,Kazutoshi Takahashi,Mayu Yamane,Shota Tomida,Saori Nakamura,Koichi Oshima,Akira Niwa,Ryuta Nishikomori,Naotomo Kambe,Hideki Hara,Masao Mitsuyama,Nobuhiro Morone,John E. Heuser,Takuya Yamamoto,Akira Watanabe,Aiko Sato-Otsubo,Seishi Ogawa,Isao Asaka,Toshio Heike,Shinya Yamanaka,Tatsutoshi Nakahata,Megumu K. Saito
Platelets and Thrombopoiesis
Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia
Jérôme Rollin,Claire Pouplard,Marie-Pierre Gratacap,Dorothée Leroux,Marc-Antoine May,Michel Aupart,Valérie Gouilleux-Gruart,Bernard Payrastre,Yves Gruel
Intracellular cyclophilin A is an important Ca2+ regulator in platelets and critically involved in arterial thrombus formation
Margitta Elvers,Annika Herrmann,Peter Seizer,Patrick Münzer,Sandra Beck,Tanja Schönberger,Oliver Borst,Francisco Javier Martin-Romero,Florian Lang,Andreas E. May,Meinrad Gawaz
Transplantation
Vascular Biology
-
Cover Image
Cover Image
![issue cover]()
The cover shows efflux of 0.45-μm red microspheres from the vascular circulation (labeled in green) toward collagen matrix (in blue) within an inflamed joint of a mouse. These observations document the presence of gaps between endothelial cells in the vasculature during inflammation, consistent with increased tissue edema and likely similar to human inflammatory conditions such as arthritis. Although platelets are conventionally assigned the role of preserving vascular integrity, they are capable of triggering the formation of gaps during inflammation via serotonin release, a process inhibited by serotonin-specific reuptake inhibitor antidepressant drugs. This demonstration that platelets are capable of amplifying and maintaining vascular permeability adds to the rapidly growing list of unexpected functions for platelets. See the article by Cloutier et al on page 1334.
- PDF Icon Front MatterFront Matter
- PDF Icon Table of ContentsTable of Contents
- PDF Icon Back MatterBack Matter
- PDF Icon AdvertisingAdvertising
- PDF Icon Editorial BoardEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
